IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

AZZAOUI ET AL.

APPLICATION NO: 10/586,422

FILED: 19 July 2006

FOR: INDOL-ALANINE DERIVATIVES AS SELECTIVE S1P4-AGONISTS

MS: Amendments Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Sir:

In response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed on 24 October 2007 and with a Two (2) Month Extension of Time fee extending the period of reply for this response to 24 February 2008, applicants enter the following Preliminary Amendment:

Prior to the examination of the above-referenced patent application, please make the following Amendment to the Specification:

Insert the attached Sequence Listing at the end of the Specification preceding the Claims.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc. 400 Technology Square Cambridge, MA 02139 (617) 871-3027

Date: 2-15-08

Mei I Benni

Attorney for Applicants

Reg. No. 45,470